 | Up a level |
Juillerat, P; Wasan, SK; Fowler, SA; Yajnik, V; Korzenik, JR; Pabby, VK; Friedman, S; Coukos, JA; Barto, AE; Pellish, R; and Farraye, FA (2012). Efficacy and Safety of Natalizumab in Crohn’s Disease Patients Treated at 5 Academic Hospitals. Journal of Crohn's & Colitis, 6(Supplement 1), p. 128. Amsterdam: Elsevier
Juillerat, Pascal; Sokol, H; Froehlich, F; Burnand, B; Yajnik, V; Beaugerie, L; Macpherson, Andrew; Cosnes, J; Korzenik, JR (2014). Facteurs associés à une réponse à l’infliximab prolongée au-delà de 5 ans : une étude de cohorte multi-centrique internationale (Unpublished). In: Journées Francophones d’Hépatologie-gastroentérologie et d’Oncologie Digestives. Paris.
Juillerat, P; Schneeweiss, S; Mogun, H; Cook, EF; Ananthakrishnan, AN; Korzenik, JR (2011). New H2-eceptor Antagonist Use May Increase Risk of Surgery or Hospitalization in Crohn's Disease While PPI Use May Be Associated With Ulcerative Colitis Flares. Differential Effects of Acid Suppressing Agents in IBD. In: Digestive Disease Week.
